🇺🇸 Piperacillin / Tazobactam Injection in United States
169 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 169
Most-reported reactions
- Pyrexia — 31 reports (18.34%)
- Condition Aggravated — 21 reports (12.43%)
- Rash — 20 reports (11.83%)
- Aspartate Aminotransferase Increased — 16 reports (9.47%)
- Alanine Aminotransferase Increased — 15 reports (8.88%)
- Thrombocytopenia — 14 reports (8.28%)
- Blood Alkaline Phosphatase Increased — 13 reports (7.69%)
- Gamma-Glutamyltransferase Increased — 13 reports (7.69%)
- Neutropenia — 13 reports (7.69%)
- Renal Failure Acute — 13 reports (7.69%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Piperacillin / Tazobactam Injection approved in United States?
Piperacillin / Tazobactam Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Piperacillin / Tazobactam Injection in United States?
Rambam Health Care Campus is the originator. The local marketing authorisation holder may differ — check the official source linked above.